Vol. 22/No. 03

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.

Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.

Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.

Neal D. Shore, MD, discusses the FDA approval of relugolix in prostate cancer.

Formerly, small cell lung cancer was generally considered more chemotherapy sensitive in the short term but also associated with an overall inferior survival outcome; however, the difference in prognosis compared with metastatic non–small cell lung cancer was measured in months—rarely longer.

Although safety remains a concern with gene therapy, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cured cancers will follow.

Investigators are seeking to determine whether seribantumab, a novel monoclonal antibody, can effectively treat patients with solid tumors that harbor rare NRG1 fusions.